Room temperature palladium-catalyzed cross coupling of aryltrimethylammonium triflates with aryl Grignard reagents.

Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, USA.
Organic Letters (Impact Factor: 6.14). 10/2010; 12(19):4388-91. DOI: 10.1021/ol1018739
Source: PubMed

ABSTRACT Aryltrimethylammonium triflates and tetrafluoroborates were found to be highly reactive electrophiles in the Pd-catalyzed cross coupling with aryl Grignard reagents. The coupling reactions proceed at ambient temperature with a nearly stoichiometric quantity of Grignard reagent, and diverse functionality is tolerated. Competition experiments established the reactivity of PhNMe(3)OTf relative to PhCl, PhBr, PhI, and PhOTf.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Lithium and nickel complexes bearing quinoline-based ligands have been synthesized and characterized. Reaction of 8-azidoquinoline with Ph(2)PNHR (R = p-MeC(6)H(4), Bu(t)) affords N-(8-quinolyl)iminophosphoranes RNHP(Ph(2))=N(8-C(9)H(6)N) (1a, R = p-MeC(6)H(4); 1b, R = Bu(t). C(9)H(6)N = quinolyl)). Reaction of 1a with (DME)NiCl(2) generates a nickel complex [NiCl(2){N(8-C(9)H(6)N)=P(Ph(2))NH(p-MeC(6)H(4))}] (2a). Treatment of 1b with (DME)NiCl(2) and following with NaH produces [NiCl{(1,2-C(6)H(4))P(Ph)(NHBu(t))=N(8-C(9)H(6)N)}] (4). Complex 4 was also obtained by reaction of (DME)NiCl(2) with [Li{(1,2-C(6)H(4))P(Ph)(NHBu(t))=N(8-C(9)H(6)N)}] (5) prepared through lithiation of 1b. Reaction of 2-PyCH(2)P(Ph(2))=N(8-C(9)H(6)N) (6, Py = pyridyl) and PhN=C(Ph)CH(2)P(Ph(2))=N(8-C(9)H(6)N) (8), respectively, with (DME)NiCl(2) yields two five-coordinate N,N,N-chelate nickel complexes, [NiCl(2){2-PyCH(2)P(Ph(2))=N(8-C(9)H(6)N)}] (7) and [NiCl(2){PhN=C(Ph)CH(2)P(Ph(2))=N(8-C(9)H(6)N)}] (9). Similar reaction between Ph(2)PCH(2)P(Ph(2))=N(8-C(9)H(6)N) (10) and (DME)NiCl(2) results in five-coordinate N,N,P-chelate nickel complex [NiCl(2){Ph(2)PCH(2)P(Ph(2))=N(8-C(9)H(6)N)}] (11). Treatment of [(8-C(9)H(6)N)N=P(Ph(2))](2)CH(2) (12) [prepared from (Ph(2)P)(2)CH(2) and 2 equiv. of 8-azidoquinoline] with LiBu(n) and (DME)NiCl(2) successively affords [NiCl{(8-C(9)H(6)N)NP(Ph(2))}(2)CH] (13). The new compounds were characterized by (1)H, (13)C and (31)P NMR spectroscopy (for the diamagnetic compounds), IR spectroscopy (for the nickel complexes) and elemental analysis. Complexes 2a, 4, 7, 9, 11 and 13 were also characterized by single-crystal X-ray diffraction techniques. The nickel complexes were evaluated for the catalysis in the cross-coupling reactions of arylzinc reagents with aryl chlorides and aryltrimethylammonium salts. Complex 7 exhibits the highest activity among the complexes in catalyzing the reactions of arylzinc reagents with either aryl chlorides or aryltrimethylammonium bromides.
    Dalton Transactions 07/2012; 41(34):10453-64. · 3.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This tutorial review is intended to provide the reader with a timely review of major developments and the current state-of-the-art of palladium-catalyzed cross-coupling reactions with Grignard reagents. Organomagnesium reagents, the most reactive and most easily accessible nucleophiles for carbon-carbon bond forming cross-coupling reactions, were the first nucleophiles ever employed in cross-coupling reactions, but have only recently been re-discovered for highly efficient and (stereo)selective coupling reactions. This is mostly a consequence of improved catalyst systems with bulky phosphine, phosphonate or carbene ligands and new metal-halogen exchange procedures for the generation of functionalized Grignard reagents.
    Chemical Society Reviews 08/2011; 40(10):4948-62. · 24.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction The urokinase plasminogen activator (uPA) system is a proteolytic cascade involved in tumor invasion and metastasis. uPA and its inhibitor PAI-1 are described as biomarkers for breast cancer with the highest level of evidence. The present study describes the synthesis and first in vivo application of an activity based uPA PET-probe. Methods Based on the design of a small irreversible and selective uPA-inhibitor we developed a 18 F-labeled activity based probe for uPA imaging. Human uPA expressing MDA-MB-231-luc2-GFP cells were inoculated in the mammary fat pads of nude mice and treated with the probe once tumors reached a volume of 150 mm3. Scans were performed at 0.25, 0.75, 1.5, 4 and 6 h post injection. To evaluate tumor uptake in vivo and ex vivo data were gathered. Biodistribution data of the organs and tissues of interest were collected at all time points. Due to a relatively low tumor uptake, probe stability was further evaluated. Results The uPA targeting PET tracer was produced in high purity and with good specific radioactivity. In vivo PET data showed a maximum tumor uptake of 2,51 ± 0,32 %ID/g at 4 h p.i. A significant correlation between in vivo and ex vivo tumor uptake calculation was found (R = 0.75; p < 0.01). Due to a high blood signal at all time points, probe stability was further examined revealing high plasma protein binding and low plasma stability. Conclusions In vivo and ex vivo results clearly demonstrate that uPA expressing tumors can be detected with non-invasive PET imaging. Stability tests suggest that further optimization is needed to provide a better tumor-to-background contrast.
    Nuclear Medicine and Biology 01/2014; · 2.52 Impact Factor